NHS availability is unlikely before the mid-to-late 2020s at the earliest, as retatrutide must first complete phase 3 trials, receive MHRA marketing authorisation, and undergo a NICE health technology appraisal to assess its clinical and cost-effectiveness
Exercise: Regular physical activity can help increase glutathione levels and improve overall metabolic health
Some research suggests GLP-1 medications may benefit patients with cardiovascular disease by lowering blood pressure, improving cholesterol, and reducing inflammation
Management of type 2 diabetes: Australian rural and remote general practitioners knowledge, attitudes, and practices
What is the downside of ipamorelin
2 Kidney Disease Risk Reduction In addition, the FDA has approved semaglutide (Ozempic) to slow the progression of kidney disease and reduce the risk of kidney failure, making it the most widely indicated GLP-1 drug